Louise Rice,Balaji Ganeshan,Simon Wan,Shih-Hsin Chen,David M L Lilburn,Manuel Rodriguez-Justo,Stuart Taylor,Robert I Shortman,Raymond Endozo,Saif Khan,Luke R Hoy,Daren Francis,Tan Arulampalam,Nicholas Reay-Jones,Kenneth A Miles,Ashley M Groves
{"title":"Texture analysis of [18F]FDG PET/CT may stratify risk in stage II colorectal cancer - discovery findings.","authors":"Louise Rice,Balaji Ganeshan,Simon Wan,Shih-Hsin Chen,David M L Lilburn,Manuel Rodriguez-Justo,Stuart Taylor,Robert I Shortman,Raymond Endozo,Saif Khan,Luke R Hoy,Daren Francis,Tan Arulampalam,Nicholas Reay-Jones,Kenneth A Miles,Ashley M Groves","doi":"10.1007/s00259-025-07568-6","DOIUrl":null,"url":null,"abstract":"RATIONALE\r\nIt is challenging to identify which patients with Stage II colorectal cancer (T3N0M0 and T4N0M0) are at high risk of recurrence and might benefit from additional therapies. This preliminary study examines whether multiparametric [18F]FDG PET/CT is superior to T-stage in predicting overall survival in this patient group.\r\n\r\nMATERIALS AND METHODS\r\nThis multicentre, prospective observational study included 66 patients (41 male, 25 female, mean age 69.1 ± 10.3yrs) with biopsy-proven Stage II colorectal cancer who underwent [18F]FDG PET/CT prior to resection. Kaplan-Meier analysis was performed on PET and image texture parameters and clinico-histopathological markers to identify associations with survival. P-values were adjusted using the Benjamini-Hochberg procedure, and the most statistically significant radiomic parameters underwent 3-fold cross-validation. Multivariate Cox regression analysis was used to determine independence of prognostic markers.\r\n\r\nRESULTS\r\n49 patients survived the follow up period, with a mean overall survival of 88.4 (± 42.3 months). Univariate analysis showed no significant survival association with clinical variables such as patient sex (p = 0.295), age (p = 0.085), tumour side (p = 0.662), location (p = 0.848) or volume (p = 0.782), or high-risk histopathological metrics including low number lymph node sampling (p = 0.363), perineural, lymphovascular or extramural tumour invasion (p = 0.196), poor tumour differentiation (p = 0.372), and tumour perforation (p = 0.475). No significant survival difference was observed between T3 and T4-stages (p = 0.748). An increased mortality risk was observed for patients with a pixel mean intensity < 20.390 on CT texture (coarse texture scale), HR: 3.40 (1.36-8.49); p = 0.005, and where SUVmax ≥ 25.560 g/mL on [18F]FDG PET/CT, HR: 3.45 (1.31-9.12); p = 0.008. These parameters remained significant after 3-fold cross validation and were independent predictors of survival after Multivariate Cox regression analysis. A higher mortality risk was indicated when the parameters were combined (5 of 66 patients), hazard ratio: 5.44 (1.75-16.91); p = 0.001.\r\n\r\nCONCLUSION\r\nMultiparametric [18F]FDG PET/CT can potentially provide prognostic markers for patients with stage II colorectal cancer with superior risk stratification compared to T-stage.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"18 1","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-025-07568-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
RATIONALE
It is challenging to identify which patients with Stage II colorectal cancer (T3N0M0 and T4N0M0) are at high risk of recurrence and might benefit from additional therapies. This preliminary study examines whether multiparametric [18F]FDG PET/CT is superior to T-stage in predicting overall survival in this patient group.
MATERIALS AND METHODS
This multicentre, prospective observational study included 66 patients (41 male, 25 female, mean age 69.1 ± 10.3yrs) with biopsy-proven Stage II colorectal cancer who underwent [18F]FDG PET/CT prior to resection. Kaplan-Meier analysis was performed on PET and image texture parameters and clinico-histopathological markers to identify associations with survival. P-values were adjusted using the Benjamini-Hochberg procedure, and the most statistically significant radiomic parameters underwent 3-fold cross-validation. Multivariate Cox regression analysis was used to determine independence of prognostic markers.
RESULTS
49 patients survived the follow up period, with a mean overall survival of 88.4 (± 42.3 months). Univariate analysis showed no significant survival association with clinical variables such as patient sex (p = 0.295), age (p = 0.085), tumour side (p = 0.662), location (p = 0.848) or volume (p = 0.782), or high-risk histopathological metrics including low number lymph node sampling (p = 0.363), perineural, lymphovascular or extramural tumour invasion (p = 0.196), poor tumour differentiation (p = 0.372), and tumour perforation (p = 0.475). No significant survival difference was observed between T3 and T4-stages (p = 0.748). An increased mortality risk was observed for patients with a pixel mean intensity < 20.390 on CT texture (coarse texture scale), HR: 3.40 (1.36-8.49); p = 0.005, and where SUVmax ≥ 25.560 g/mL on [18F]FDG PET/CT, HR: 3.45 (1.31-9.12); p = 0.008. These parameters remained significant after 3-fold cross validation and were independent predictors of survival after Multivariate Cox regression analysis. A higher mortality risk was indicated when the parameters were combined (5 of 66 patients), hazard ratio: 5.44 (1.75-16.91); p = 0.001.
CONCLUSION
Multiparametric [18F]FDG PET/CT can potentially provide prognostic markers for patients with stage II colorectal cancer with superior risk stratification compared to T-stage.
期刊介绍:
The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.